The DEA Telemedicine Cliff: Controlled-Substance Prescribing Rules for MIH and Hospice in 2026

Why a Prescribing Rule Belongs in an EMS Brief

If your agency runs mobile integrated health (MIH), community paramedicine, or supports home hospice, the rules on how a clinician can legally order a controlled substance remotely are operational, not academic. They decide whether a physician can authorize the morphine in a hospice comfort kit, or start buprenorphine for a patient we just met in their living room, without an in-person exam first.

The Underlying Law: Ryan Haight

The default rule comes from the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, now codified at 21 U.S.C. 829(e). It says a controlled substance delivered, distributed, or dispensed by means of the internet needs a valid prescription, and a valid prescription generally requires at least one in-person medical evaluation by the prescriber. The statute carves out "the practice of telemedicine" in a short list of defined situations, one of which is a special registration DEA was supposed to create and never did.

The COVID-19 public health emergency lowered that wall temporarily. The emergency ended in May 2023; the flexibility did not, and it has been extended year by year ever since.

Where Things Stand in Late 2026

The current authority is the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, published jointly by DEA and HHS on December 31, 2025 (90 FR 61301). The key points:

• Effective window: January 1, 2026 through December 31, 2026. It amends the sunset date in 21 CFR 1307.41 and its HHS twin at 42 CFR 12.1.
• Scope: DEA-registered practitioners may prescribe Schedule II–V controlled medications through a telemedicine encounter without a prior in-person evaluation, as long as the prescription is for a legitimate medical purpose in the usual course of practice, the practitioner is registered for that schedule, and the prescription meets every other requirement of 21 CFR Part 1306.
• State law still applies. The federal flexibility does not override state prescribing rules or licensure requirements.

The reason it keeps coming as a one-year extension rather than a permanent rule is that the Special Registration for Telemedicine framework has not been finalized. DEA proposed it on January 17, 2025 (90 FR 6541) and received more than 6,400 comments. As I write this in October 2026, no final Special Registration rule has been published in the Federal Register.

The Buprenorphine Rule Is Separate, and Already Final

Opioid use disorder has its own pathway. The final rule Expansion of Buprenorphine Treatment via Telemedicine Encounter (90 FR 6504, now 21 CFR 1306.51) took effect on December 31, 2025 after two delays. Its terms are worth knowing cold if your MIH program touches OUD:

• It covers Schedule III–V narcotics FDA-approved for OUD, which in practice means buprenorphine.
• The prescriber may use audio-only or audio-video telemedicine with no prior in-person exam.
• Before prescribing, the practitioner must check the PDMP for the state where the patient is located. If the PDMP is unreachable, the supply is capped at seven days until the check succeeds.
• The initial supply is capped at six calendar months in total. After that, continued prescribing needs an in-person evaluation or another form of telemedicine the Controlled Substances Act allows.
• The pharmacist must verify the patient's identity before filling.

The extension rule notes that a prescriber may still use the broader temporary flexibility while it lasts. The buprenorphine rule is the floor that remains after December 31.

What the Proposed Special Registration Would Change

The January 2025 proposal is not law, but it shows where DEA is heading:

Clinicians would also need a DEA-issued State Telemedicine Registration for each state where they prescribe remotely, and would eventually face a PDMP check across every state. The proposed fee is $888 per special registration. That hospice and palliative care physicians are named for Schedule II matters to us: it signals DEA expects remote Schedule II prescribing for end-of-life symptom control to survive in some form, behind a heavier credentialing wall.

What It Means for Our Verticals

• Hospice at the bedside: through December 31, a covering physician can authorize controlled medications for a symptom crisis by telehealth. The remote order does not loosen the count. Pharmacy records under 21 CFR Part 1304, the hospice's own drug-disposal policies, and our documentation still have to reconcile every dose.
• MIH and OUD: buprenorphine induction from a home visit now rests on a final rule, not a temporary one. The six-month limit and the PDMP check are the details to build into your protocol.
• The cliff risk: if neither a fifth extension nor a final Special Registration rule is published before January 1, 2027, the in-person requirement returns for every controlled substance outside the buprenorphine rule, the VA continuity-of-care rule, and the narrow statutory telemedicine exceptions. Build workflows that can absorb that change.

For documentation, the framework to keep in view is 21 CFR Part 1304 recordkeeping plus electronic prescribing of controlled substances (EPCS) under 21 CFR Part 1311. The clinical flexibility is real; the compliance burden did not go anywhere.

Sources

• Federal Register — Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (90 FR 61301)
• Federal Register — Expansion of Buprenorphine Treatment via Telemedicine Encounter, final rule (90 FR 6504)
• Federal Register — Special Registrations for Telemedicine, proposed rule (90 FR 6541)
• Cornell LII — 21 U.S.C. 829, Ryan Haight in-person evaluation requirement
• eCFR — 21 CFR 1307.41, temporary telemedicine prescribing authority
• eCFR — 21 CFR Part 1311, electronic prescriptions for controlled substances

Reviewed against the Federal Register, DEA and eCFR pages on 17 October 2026.